Overweight and obesity are not associated with worse clinical outcomes in COVID-19 patients treated with fixed-dose 6 mg dexamethasone

Autor: Wittermans, Esther, Grutters, Jan C., Moeniralam, Hazra S., Ocak, Gurbey, Paul Voorn, G., Bos, Willem Jan W., van de Garde, Ewoudt M.W., Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology

Publikováno v: International Journal of Obesity, 46(11), 2000-2005. SPRINGERNATURE
International Journal of Obesity, 46(11), 2000. Nature Publishing Group

Objective: A fixed 6 mg dexamethasone dose for 10 days is the standard treatment for all hospitalised COVID-19 patients who require supplemental oxygen. Yet, the pharmacokinetic properties of dexamethasone can lead to diminishing systemic dexamethaso

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::92ad3857bf7f82e4acb14b050b1d8b7d
https://doi.org/10.1038/s41366-022-01204-1

Clinical features predicting failure of pathogen identification in patients with community acquired pneumonia.

Autor: Endeman, Henrik, Schelfhout, Vanessa, Paul Voorn, G., van Velzen-Blad, Heleen, Grutters, Jan C., Biesma, Douwe H.

Publikováno v: Scandinavian Journal of Infectious Diseases; Sep2008, Vol. 40 Issue 9, p715-720, 6p, 4 Charts